Key facts
- Latigo Bio’s last known valuation is $530.0M (Mar 2025).
- It has raised $304.0M; the latest was Later Stage VC ($150.0M) in Mar 2025.
- Notable investors include Alexandria Venture Investments, Qatar Investment Authority, Blue Owl Capital, Foresite Capital, Cormorant Asset Management — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Latigo Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Latigo Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Latigo Bio
Operator of a biotechnology company intended to develop novel and non-opioid therapies for chronic pain. The company's platform offers translated insights to provide a differentiated approach to targeting therapeutics across the blood-nerve barrier, enabling patients to get access to a pain management therapy that does not create addiction, dependence, or tolerability.
- Sector
- Healthcare
- HQ
- Thousand Oaks, CA, United States
- Founded
- 2018
- Employees
- 44
- Website
- latigobio.com/
- Ownership
- Privately Held (backing)
Latigo Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Latigo Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Latigo Bio in its N-PORT filings yet. We sweep new filings monthly.